Last updated: 2026-10-13 23:46:00. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Foghorn Therapeutics Inc. (FHTX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $1.86, with a market capitalisation of $118.77M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.79 to $7.61. This page covers its latest market performance, valuation, price trends and company information.
$118.77M | |
$1.95 | |
$28.27 | |
$1.79 | |
$1.95 | |
796.78K | |
646.81K | |
-- | |
$7.61 | |
$1.79 | |
-- | |
-- |
Foghorn Therapeutics Inc. (FHTX) is trading at $1.92 in after-hours trading as of 2026-10-13 23:31:00, down 1.74% ($0.03) from the regular-session close of $1.95.
After-hours trading shows how investors are pricing FHTX after the regular session closes. The current after-hours price is below the regular-session close, indicating cautious after-hours sentiment.
Over the past seven days, Foghorn Therapeutics Inc. (FHTX) moved from $2.02 to $1.86, representing a decline of 8.02% ($0.16).
The stock traded between $1.84 and $2.91 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 1.13 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 1.2%
FHTX is currently trading at $1.86, placing it 1.2% of the way from its 52-week low of $1.79 to its 52-week high of $7.61. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 106 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Foghorn Therapeutics Inc. (FHTX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.